Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.
Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.